모노아민 산화효소 억제제 시장 예측(2026-2032년)

The Monoamine Oxidase Inhibitors Drugs Market is projected to grow by USD 2.57 billion at a CAGR of 7.31% by 2032.

Monoamine Oxidase Inhibitors in Contemporary Neuropsychiatric Care

Monoamine oxidase inhibitors (MAOIs) are prescription medicines used primarily in selected depressive disorders and, for certain formulations, Parkinson's disease. They act by reducing the breakdown of monoamine neurotransmitters, including serotonin, norepinephrine, and dopamine. Their clinical use is constrained by food and medicine interactions, adverse-effect risks, and the availability of other therapies, but they remain relevant when treatment response is inadequate or specific clinical needs justify their use.

Safety Management and Treatment Positioning Are Reshaping Use

The landscape is being shaped by stronger emphasis on medication reconciliation, dietary counseling, interaction screening, and specialist supervision. Clinicians must distinguish between irreversible and reversible inhibition, account for washout periods, and manage risks associated with hypertensive reactions or serotonin toxicity. Transdermal and selective formulations may reduce some practical barriers, while individualized treatment selection and closer follow-up are increasing the importance of patient education and coordinated care.

Artificial Intelligence Supports Safer, More Individualized Decisions

Artificial intelligence can contribute to MAOI care by identifying potential drug interactions across complex medication lists, flagging contraindicated combinations, and supporting clinical decision workflows. It may also assist pharmacovigilance by detecting patterns in adverse-event reports and help researchers identify patient characteristics associated with response or intolerance. These applications require validated clinical evidence, transparent reasoning, privacy safeguards, and clinician oversight; AI should support, rather than replace, prescribing judgment.

Regional Differences Reflect Regulation, Access, and Specialist Capacity

In North America and Europe, use is influenced by established prescribing guidance, specialist services, and detailed interaction-management requirements. Asia-Pacific combines advanced neuropsychiatric care in countries such as Australia, Japan, and South Korea with substantial variation in access and clinical infrastructure across the region. Latin America, the Middle East, and Africa face differing levels of medicine availability, psychiatric workforce capacity, and continuity of care. Across all regions, reliable supply, prescriber training, and patient counseling are central to safe utilization.

Economic and Policy Groups Show Uneven Health-System Readiness

Within ASEAN, differences in regulatory systems, specialist availability, and medicine procurement affect implementation. BRICS members span highly varied healthcare capacity, disease burdens, and access pathways. The European Union benefits from coordinated regulatory principles but retains national differences in reimbursement and clinical practice. G7 systems generally have mature pharmacovigilance and specialist networks, while GCC countries are expanding healthcare capacity with varied approaches to access. NATO members likewise differ in national formularies and mental-health infrastructure, making group-level coordination useful but insufficient without country-specific planning.

Country Context Determines Practical Adoption and Monitoring

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally have established regulatory and clinical frameworks for managing complex antidepressant therapy, although formularies and prescribing practices differ. Brazil, Mexico, India, China, Russia, and other covered markets show variation in specialist access, procurement, diagnostic capacity, and continuity of treatment. Country-level priorities include consistent labeling, interaction-aware electronic prescribing, availability of trained clinicians, and clear pathways for monitoring adverse effects and treatment transitions.

Prioritize Safe Access, Specialist Training, and Evidence Generation

Industry leaders should strengthen interaction-screening tools, provide concise dietary and medication counseling, and support education for prescribers, pharmacists, and patients. Product planning should account for formulation-specific safety requirements, reliable distribution, and clear transition guidance. Partnerships with health systems can improve pharmacovigilance and adherence support, while real-world studies should examine effectiveness, tolerability, and access across diverse populations. Any digital or AI-enabled solution should undergo clinical validation and integrate explicit human review.

Evidence Synthesis Across Clinical, Regulatory, and Health-System Sources

This executive summary is based on a structured interpretation of the supplied market scope, supplemented conceptually by established clinical and regulatory considerations for MAOIs. A rigorous full study would triangulate prescribing information, treatment guidelines, peer-reviewed literature, pharmacovigilance records, regulatory databases, formulary documents, and interviews with clinicians and pharmacists. Findings should be cross-checked across geographies, separated by formulation and indication, and assessed for evidence quality, recency, and applicability. No market estimates, market shares, or forecasts are used here.

MAOIs Remain Specialized Therapies Requiring Disciplined Stewardship

Monoamine oxidase inhibitors retain a defined role in neuropsychiatric care despite demanding safety requirements and competition from alternative treatments. Their future relevance depends less on broad use than on appropriate patient selection, dependable access, rigorous interaction management, and informed specialist oversight. Regional and country differences make adaptable implementation essential, while validated digital tools and carefully governed AI may improve safety, monitoring, and treatment personalization.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Monoamine Oxidase Inhibitors Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Major Depressive Disorder
  • 7.2.1. Atypical Depression
  • 7.2.2. Treatment Resistant Depression
• 7.3. Parkinson's Disease
  • 7.3.1. Advanced Stage
  • 7.3.2. Early Stage

8. Monoamine Oxidase Inhibitors Drugs Market, by Molecule Type

• 8.1. Introduction
• 8.2. Non-Selective MAO Inhibitors
  • 8.2.1. Isocarboxazid
  • 8.2.2. Phenelzine
  • 8.2.3. Tranylcypromine
• 8.3. Selective MAO-B Inhibitors
  • 8.3.1. Rasagiline
  • 8.3.2. Safinamide
  • 8.3.3. Selegiline

9. Monoamine Oxidase Inhibitors Drugs Market, by Route of Administration

• 9.1. Introduction
• 9.2. Oral
• 9.3. Transdermal

10. Monoamine Oxidase Inhibitors Drugs Market, by Formulation

• 10.1. Introduction
• 10.2. Capsule
• 10.3. Patch
• 10.4. Tablet

11. Monoamine Oxidase Inhibitors Drugs Market, by End User

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies
• 11.5. Specialty Clinics
  • 11.5.1. Neurology Clinics
  • 11.5.2. Psychiatry Clinics

12. Monoamine Oxidase Inhibitors Drugs Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Monoamine Oxidase Inhibitors Drugs Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Monoamine Oxidase Inhibitors Drugs Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc
• 16.2. Apotex Inc.
• 16.3. AstraZeneca Plc
• 16.4. Bausch Health Companies Inc.
• 16.5. Bayer AG
• 16.6. Bristol-Myers Squibb Company
• 16.7. Dr. Reddy's Laboratories Ltd.
• 16.8. Eli Lilly and Company
• 16.9. F. Hoffmann-La Roche AG
• 16.10. Gedeon Richter Plc
• 16.11. GlaxoSmithKline plc
• 16.12. Hetero Drugs Limited
• 16.13. Hikma Pharmaceuticals PLC
• 16.14. Johnson & Johnson
• 16.15. Lundbeck A/S
• 16.16. Lupin Limited
• 16.17. Novartis AG
• 16.18. Pfizer Inc.
• 16.19. Sandoz International GmbH
• 16.20. Sanofi SA
• 16.21. Servier Laboratories
• 16.22. Sun Pharmaceutical Industries Ltd
• 16.23. Teva Pharmaceutical Industries Ltd.
• 16.24. Viatris Inc.

17. Key Experts